ZURICH, May 7 (Reuters) – Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further milestone payments of up to $300 million.
The acquisition builds on a five-year partnership between Roche and PathAI that was scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms.
The deal is expected to close in the second half of 2026, and PathAI – based on Boston, Massachusetts – is due to become part of Roche’s diagnostics division.
Roche said the acquisition strengthens its position in digital pathology, which is helping to transform manual workflows into fully automated, AI-driven processes.
“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” Matt Sause, CEO of Roche Diagnostics, said in a statement.
(Writing by Dave Graham, Editing by Friederike Heine)
